Clinical trial · Observational
Prospective Measurement of Post-Treatment Lymphedema
Prospective Measurement of Post-Treatment Lymphedema in Patients With Melanoma
NCT00495950CI-TRIAL-00024899completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this study is to measure the amount of limb swelling (lymphedema) that sometimes occurs after melanoma treatment, and to find out how people feel and react to the diagnosis and treatment of melanoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Questionnaire | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Questionnaire
- interventionNames
- Behavioral: Questionnaire
Primary outcomes (1)
- measure
- Number of incidences of lymphedema following surgical treatment of stage I, II, and III cutaneous malignant melanoma
- timeFrame
- 30 Month Period
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with a confirmed diagnosis (M.D. Anderson pathology) of invasive cutaneous melanoma (stages I-III) will be recruited for participation as they present for their initial clinical evaluation to the University of Texas M.D. Anderson Melanoma and Skin Center. 2. Prior to surgical treatment 3. Patients who can knowledgeably and voluntarily provide an informed consent to participate. The informed consent will be signed and dated. 4. Fluent in English. 5. At least 18 years of age. Exclusion Criteria: 1. Patients with a prior history of lymphedema or melanoma prior to treatment. 2. Patients who are unable to consent due to other medical illnesses or disorientation to person, place or time. 3. Patients with known distant metastatic disease (Stage IV). 4. Patients with implanted device (pace maker), orthopedic implants, and metal frames. 5. Presence of concurrent malignancy that requires active treatment, such as chemotherapy or biotherapy, prior to enrollment.
References
Publications (0)
Data not yet available
No reference posted for this study.